REDWOOD CITY, Calif.,
Nov. 5, 2015 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute pain, today announced that Chief Financial Officer
Tim Morris will be presenting at the
Credit Suisse 24th Annual Healthcare Conference in Phoenix, AZ. Details of the conference
are as follows:
Credit Suisse 24th Annual Healthcare Conference
2015
Date: Wednesday, November 11
Location: The Phoenician, Phoenix,
AZ
Presentation Time: 3:30 pm local
time, 2:30 pm PT
The Credit Suisse presentation will be webcast live and can be
accessed through the Investors page at www.acelrx.com. For
those not available to listen to the live broadcast, a replay will
be archived for 90 days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute pain. The company's
late-stage pipeline includes ARX-04 (sufentanil sublingual tablet,
30 mcg) for the treatment of moderate-to-severe acute pain in a
medically supervised setting; and Zalviso™ (sufentanil sublingual
tablet system) for the management of moderate-to-severe acute pain
in adult patients in the hospital setting.
ARX-04 delivers 30 mcg sufentanil, a high therapeutic index
opioid, sublingually through a disposable, pre-filled, single-dose
applicator. AcelRx has reported positive results from the pivotal
Phase 3 SAP301 ambulatory surgery study, and has advanced ARX-04
into a study (SAP-302) in emergency room patients. Zalviso delivers
15 mcg sufentanil sublingually through a non-invasive delivery
route via a pre-programmed, patient-controlled analgesia device. In
response to the New Drug Application (NDA) AcelRx submitted to the
U.S. Food and Drug Administration (FDA) seeking approval for
Zalviso, AcelRx received a Complete Response Letter (CRL) on
July 25, 2014. The FDA has requested
an additional clinical study and the Company is working with the
FDA regarding the resubmission of the Zalviso NDA and initiation of
a clinical study to support resubmission.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-credit-suisse-24th-annual-healthcare-conference-300173006.html
SOURCE AcelRx Pharmaceuticals, Inc.